Cover Image
市場調查報告書

全球C型肝炎市場

Global Hepatitis C Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 311857
出版日期 內容資訊 英文 104 Pages
訂單完成後即時交付
價格
Back to Top
全球C型肝炎市場 Global Hepatitis C Market 2014-2018
出版日期: 2014年09月03日 內容資訊: 英文 104 Pages
簡介

C型肝炎是感染C型肝炎病毒的疾病,引起急性感染疾病或慢性感染疾病。患急性感染疾病的感染者約80%無症狀。症狀為呈現噁心、尿色深、發燒、食慾不振、臉色灰、腹痛及關節痛等形式。感染者約有20%發生黃疸。急性感染者約15-45%從感染起最初6個月以內自然恢復。這是透過免疫系統將病毒從體內被除去。消除病毒失敗的剩餘55-85%的感染者,在6個月以內發生慢性C型肝炎。根據世界衛生組織(WHO),全球1億3,000萬∼1億5,000萬人為慢性B型肝炎所苦,每年35萬人∼50萬人因C型肝炎相關的肝臟疾病死亡。現在雖然沒有預防C型肝炎的疫苗,不過可利用各種治療選項。全球C型肝炎市場預計2013年∼2018年以19.20%的CAGR成長。

本報告提供全球C型肝炎市場相關調查分析、市場規模與成長率、市場趨勢、推動市場要素與課題、市場機會驗證、主要供應商等相關的系統性資訊。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 疾病概要

  • 感染傳播形態
  • 地區分佈
  • 篩檢
  • 治療
    • WHO的指南
    • AASLD的指南

第7章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 慢性C型肝炎治療的主要上市藥

第9章 市場區隔:各MOA

  • 病毒特異性物質
    • 聚合酵素抑制劑
    • 蛋白分解酵素抑制劑
  • 非特異性物質
    • INF型藥物
    • 其他

第10章 地區區分

第11章 購買標準

第12章 推動市場成長要素

第13章 推動因素與其影響

第14章 市場課題

第15章 推動因素與課題的影響

第16章 市場趨勢

第17章 趨勢與其影響

第18章 業者情勢

  • 競爭模式
  • 市場佔有率分析
  • 其他卓越供應商

第19章 主要供應商分析(產業概要、產業區分、產業策略、SWOT分析等)

  • F. Hoffmann La Roche
  • Gilead
  • Johnson & Johnson
  • Merck
  • Vertex Pharmaceuticals

第20章 相關報告

圖表清單

目錄
Product Code: IRTNTR4050

About Hepatitis C

Hepatitis C is a liver disease caused by infection due to hepatitis C virus. Hepatitis C infection predominantly affects the liver; however, other parts of the body are also affected such as the brain and the digestive system. Hepatitis C virus is an RNA virus belonging to the family Flaviviridae and genus hepacivirus. It has a positive-sense, single-stranded RNA molecule enveloped by a lipid bilayer. Hepatitis C can lead to acute infection or chronic infection. Nearly 80 percent of the infected individuals suffering from acute infection are asymptomatic. Symptoms manifested in the rest include nausea, dark urine, fever, anorexia, gray-colored faces, abdominal pain, and joint pain. Nearly 20 percent of infected individuals develop jaundice, which is characterized by the yellowing of skin and eyes. Nearly 15-45 percent of acutely infected individuals recover from the infection spontaneously within the first six months of infection. This happens because the immune system mediated the clearance of the virus from the body. The remaining 55-85 percent of infected individuals who fail to clear the virus within six months develop chronic hepatitis C phase. Chronic infection can lead to mild-to-moderate symptoms or chronic symptoms such as liver fibrosis, liver cirrhosis, and hepatic cancer. The World Health Organization (WHO) estimates that globally, 130-150 million people suffer from chronic hepatitis B. It also reported that every year 350,000-500,000 infected individuals die because of hepatitis C-related hepatic disorders. Currently, there is no vaccine for the prevention of hepatitis C infection; however, various treatment options for hepatitis C infection are available.

TechNavio's analysts forecast the Global Hepatitis C market to grow at a CAGR of 19.20 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Hepatitis C market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through sales of various drugs administered to treat chronic hepatitis caused by genotype 1-6 of hepatitis C virus.

TechNavio's report, the Global Hepatitis C Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Hepatitis C market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • F. Hoffmann-La Roche
  • Gilead Sciences
  • Johnson & Johnson
  • Merck
  • Vertex Pharmaceuticals

Other Prominent Vendors

  • Abbvie
  • Achillion Pharmaceuticals
  • Bristol-Myers Squibb
  • Mitsubishi Tanabe Pharma
  • Novartis

Market Driver

  • Increase in Injection Drug Users

For a full, detailed list, view our report

Market Challenge

  • Side-effects of Current Therapy

For a full, detailed list, view our report

Market Trend

  • Emergence of Interferon-free Therapies

For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Disease Overview

  • 06.1. Mode of Infection Transmission
  • 06.2. Geographical Distribution
  • 06.3. Screening
  • 06.4. Treatment
    • 06.4.1. WHO Guidelines
    • 06.4.2. AASLD guidelines

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Five Forces Analysis

08. Key Marketed Drugs for Treatment of Chronic Hepatitis C

09. Market Segmentation by MOA

  • 09.1. Virus-specific Agents
    • 09.1.1. Polymerase Inhibitors
    • 09.1.2. Protease Inhibitors
  • 09.2. Non-specific Agents
    • 09.2.1. IFN-based Drugs
    • 09.2.2. Others

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

  • 18.1. Competitive Scenario
    • 18.1.1. Key News
    • 18.1.2. Mergers and Acquisitions
  • 18.2. Market Share Analysis 2013
    • 18.2.1. Roche
    • 18.2.2. Merck
    • 18.2.3. Johnson and Johnson
    • 18.2.4. Vertex Pharmaceuticals
    • 18.2.5. Gilead
  • 18.3. Other Prominent Vendors

19. Key Vendor Analysis

  • 19.1. F. Hoffmann La Roche
    • 19.1.1. Key Facts
    • 19.1.2. Business Overview
    • 19.1.3. Business Segmentation by Revenue 2013
    • 19.1.4. Business Segmentation by Revenue 2012 and 2013
    • 19.1.5. Geographical Segmentation by Revenue 2013
    • 19.1.6. Business Strategy
    • 19.1.7. Recent Developments
    • 19.1.8. SWOT Analysis
  • 19.2. Gilead
    • 19.2.1. Key Facts
    • 19.2.2. Business Overview
    • 19.2.3. Geographical Segmentation by Revenue 2013
    • 19.2.4. Recent Developments
    • 19.2.5. SWOT Analysis
  • 19.3. Johnson & Johnson
    • 19.3.1. Key Facts
    • 19.3.2. Business Overview
    • 19.3.3. Business Segmentation by Revenue 2013
    • 19.3.4. Business Segmentation by Revenue 2012 and 2013
    • 19.3.5. Geographical Segmentation by Revenue 2013
    • 19.3.6. Business Strategy
    • 19.3.7. Recent Developments
    • 19.3.8. SWOT Analysis
  • 19.4. Merck
    • 19.4.1. Key Facts
    • 19.4.2. Business Overview
    • 19.4.3. Business Segmentation by Revenue 2013
    • 19.4.4. Business Segmentation by Revenue 2012 and 2013
    • 19.4.5. Sales by Geography
    • 19.4.6. Business Strategy
    • 19.4.7. Key Developments
    • 19.4.8. SWOT Analysis
  • 19.5. Vertex Pharmaceuticals
    • 19.5.1. Key Facts
    • 19.5.2. Business Overview
    • 19.5.3. Business Segmentation by Revenue 2013
    • 19.5.4. Business Segmentation by Revenue 2012 and 2013
    • 19.5.5. Geographical Segmentation by Revenue 2013
    • 19.5.6. Business Strategy
    • 19.5.7. Recent Developments
    • 19.5.8. SWOT Analysis

20. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Progression of Hepatitis C
  • Exhibit 3: Risk Factors for Hepatitis C Transmission
  • Exhibit 4: Prevalence Rates of Hepatitis C Across Different Geographies
  • Exhibit 5: Prevalence of Hepatitis C Genotypes in Tropical Latin America
  • Exhibit 6: Key Prevalence Data of Hepatitis C in East Asia and Pacific
  • Exhibit 7: Prevalence of Hepatitis C Genotypes in East Asia
  • Exhibit 8: Prevalence of Hepatitis C Genotypes in High Income Asia Pacific
  • Exhibit 9: Prevalence of Hepatitis C Genotypes in Australasia
  • Exhibit 10: Key Prevalence Data of Hepatitis C in Europe
  • Exhibit 11: Prevalence of Hepatitis C Genotypes in Eastern Europe
  • Exhibit 12: Prevalence of Hepatitis C Genotypes in Western Europe
  • Exhibit 13: Prevalence of Hepatitis C Genotypes in Central Europe
  • Exhibit 14: Key Prevalence Data of Hepatitis C in Latin America and Caribbean
  • Exhibit 15: Prevalence of Hepatitis C Genotypes in Tropical Latin America
  • Exhibit 16: Prevalence of Hepatitis C Genotypes in Andean Latin America
  • Exhibit 17: Prevalence of Hepatitis C Genotypes in Central Latin America
  • Exhibit 18: Prevalence of Hepatitis C Genotypes in South Latin America
  • Exhibit 19: Key Prevalence Data of Hepatitis C in Middle East and North Africa
  • Exhibit 20: Prevalence of Hepatitis C Genotypes in North Africa/Middle East
  • Exhibit 21: Key Prevalence Data of Hepatitis C in North America
  • Exhibit 22: Prevalence of Hepatitis C Genotypes in High Income Countries in North America
  • Exhibit 23: Key Prevalence Data of Hepatitis C in South Asia
  • Exhibit 24: Prevalence of Hepatitis C Genotypes in South Asia
  • Exhibit 25: Key Prevalence Data of Hepatitis C in Sub-Saharan Africa
  • Exhibit 26: Prevalence of Hepatitis C Genotypes in Central Sub-Saharan Africa
  • Exhibit 27: Prevalence of Hepatitis C Genotypes in East Sub-Saharan Africa
  • Exhibit 28: Prevalence of Hepatitis C Genotypes in South Sub-Saharan Africa
  • Exhibit 29: Prevalence of Hepatitis C Genotypes in West Sub-Saharan Africa
  • Exhibit 30: Screening Tests for Hepatitis C Infection
  • Exhibit 31: Global Hepatitis C Market 2013-2018 (US$ billion)
  • Exhibit 32: Global Hepatitis C Market Segmentation by MOA
  • Exhibit 33: Global Hepatitis C Market Segmentation by MOA 2013
  • Exhibit 34: Global Hepatitis C Market by Geographical Segmentation 2013
  • Exhibit 35: Geographical Segmentation of Pegasys Revenue 2013
  • Exhibit 36: Roche: Pipeline Candidates for Hepatitis C
  • Exhibit 37: Victrelis' Revenue 2011-2013 (US$ million)
  • Exhibit 38: Merck: Pipeline Candidates for Hepatitis C
  • Exhibit 39: Johnson & Johnson : Incivo's Revenue 2011-2013 (US$ million)
  • Exhibit 40: Olysio's Revenue 2014 (US$ million)
  • Exhibit 41: Vertex Pharmaceuticals: Incivek's Revenue 2011-2013 (US$ million)
  • Exhibit 42: Vertex: Pipeline Candidates for Hepatitis C
  • Exhibit 43: Gilead: Pipeline Candidates for Hepatitis C
  • Exhibit 44: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
  • Exhibit 45: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 46: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Pharmaceuticals Division)
  • Exhibit 47: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Diagnostics Division)
  • Exhibit 48: Gilead: Geographical Segmentation by Revenue 2013
  • Exhibit 49: Johnson & Johnson: Business Segmentation by Revenue 2013
  • Exhibit 50: Johnson & Johnson: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 51: Johnson & Johnson: Geographical Segmentation by Revenue 2013
  • Exhibit 52: Merck & Co. Inc.: Business Segmentation by Revenue 2013
  • Exhibit 53: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 54: Merck & Co. Inc.: Sales by Geography 2013
  • Exhibit 55: Vertex Pharmaceuticals: Business Segmentation by Revenue 2013
  • Exhibit 56: Vertex Pharmaceuticals: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Back to Top